Skip to content

BOTOX® Treatment in Pediatric Lower Limb Spasticity

BOTOX® Treatment in Pediatric Lower Limb Spasticity: Double-blind Study

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01603628
Enrollment
384
Registered
2012-05-22
Start date
2012-09-11
Completion date
2017-06-28
Last updated
2018-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Palsy, Muscle Spasticity, Pediatrics

Brief summary

This study will evaluate the safety and efficacy of BOTOX® (botulinum toxin Type A) in pediatric patients with lower limb spasticity.

Interventions

BIOLOGICALbotulinum toxin Type A

Participants received intramuscular injections of botulinum toxin Type A into specified muscles of the lower limb on Day 1.

DRUGNormal Saline (Placebo)

Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb on Day 1.

Sponsors

Allergan
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
2 Years to 16 Years
Healthy volunteers
No

Inclusion criteria

* Minimum weight of 10 kg/22 lb * Cerebral palsy with dynamic muscle contracture /spasticity of the ankle

Exclusion criteria

* Muscular dystrophy, myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or mitochondrial disease * Uncontrolled epilepsy * Botulinum Toxin therapy of any serotype for any condition within the last 6 months * History of surgical intervention of the lower study leg or planned surgery of any limb during the study * Previous casting of the study limb for spasticity within 6 months or with a dynamic splint within 3 months, or planned casting or dynamic splinting for spasticity of the study limb or affected upper limb during the study

Design outcomes

Primary

MeasureTime frameDescription
Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score With Knee Extended at Weeks 4 and 6Baseline (Day 1) to Weeks 4 and 6The MAS-B was used to evaluate spasticity based on grading the resistance encountered in the principal muscle group (elbow and wrist) by means of passively moving a limb through its range of motion at a study specified velocity. The resistance encountered to passive stretch was graded using a 6-point scale where: 0=no increase in muscle tone (best) to 4=affected part(s) rigid in flexion or extension (worst). For analysis purposes, the MAS-B was recoded as follows: 0=1, 1=1, 1+=2, 2=3, 3=4, 4=5. The scores at Weeks 4 and 6 were averaged. A Mixed Model Repeated Measures (MMRM) model was used for analysis. A negative change from Baseline indicates improvement.
Average Clinical Global Impression (CGI) of Overall Change by Physician at Weeks 4 and 6Weeks 4 and 6The CGI of overall change (improvement or worsening) was assessed by the physician considering the participant's clinical condition and severity of side effects using a 9-point scale where: -4=very marked worsening to +4=very marked improvement. The scores at Weeks 4 and 6 were averaged. A Mixed Model Repeated Measures (MMRM) model was used for analysis.

Secondary

MeasureTime frameDescription
Goal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeeks 8 and 12Two functional goals, one active and one passive, were selected by the participant and family in consultation with the physician investigator and/or treating physical therapist relative to the lower limb impairment due to spasticity. The physician assessed the achievement of the goals using a 6-point scale: where -3=worse than start to +2=much more than expected: improvements clearly exceed the defined therapeutic goal. An Analysis of Covariance (ANCOVA) model was used for analysis.
Change From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Baseline (Day 1) to Weeks 2, 4, 6, 8 and 12The MTS measured the difference between slow and fast range of motion (R2-R1) and respective change from baseline to each posttreatment office visit. The MTS of the ankle was used to determine the passive range of movement at different movement velocities, V1 (as slow as possible) and V3 (as fast as possible) with the relative difference between a slow and fast velocity passive stretch determining the dynamic component of the muscle contracture for the joint. The investigator measured 2 joint angles by goniometer: the R1 angle which is the angle of catch after a fast velocity (V3) stretch and the R2 angle defined as the passive joint range of movement following a slow velocity (V1) stretch. The R2-R1 value indicated the level of the dynamic component of spasticity in the joint. The difference between R2 and R1 range of motion and respective change from baseline to each posttreatment office visit on the MTS was derived. An Analysis of Covariance (ANCOVA) model was used for analysis.

Countries

Hungary, Italy, Philippines, Poland, Russia, South Korea, Thailand, Turkey (Türkiye), United States

Participant flow

Pre-assignment details

Pediatric participants with lower limb spasticity were randomized 1:1:1 to one of three treatment groups: BOTOX® 4 or 8 U/kg (unit per kilogram) or placebo.

Participants by arm

ArmCount
BOTOX® 8 U/kg
Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly physical therapy (PT).
128
BOTOX® 4 U/kg
Participants received intramuscular injections of BOTOX® (botulinum toxin Type A) 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb on Day 1. Participants received weekly PT.
126
Placebo
Participants received intramuscular injections of normal saline (placebo) into specified muscles of the lower limb. Participants received weekly PT.
130
Total384

Withdrawals & dropouts

PeriodReasonFG000FG001FG002
Overall StudyLost to Follow-up010
Overall StudyOther Miscellaneous Reason100
Overall StudyPersonal Reasons112
Overall StudyProtocol Violation110

Baseline characteristics

CharacteristicBOTOX® 8 U/kgBOTOX® 4 U/kgPlaceboTotal
Age, Continuous6.7 years
STANDARD_DEVIATION 3.9
6.4 years
STANDARD_DEVIATION 3.58
6.6 years
STANDARD_DEVIATION 3.89
6.6 years
STANDARD_DEVIATION 3.79
Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score with Knee Extended3.5 score on a scale
STANDARD_DEVIATION 0.52
3.5 score on a scale
STANDARD_DEVIATION 0.53
3.5 score on a scale
STANDARD_DEVIATION 0.5
3.5 score on a scale
STANDARD_DEVIATION 0.52
Race/Ethnicity, Customized
Asian
42 Participants35 Participants38 Participants115 Participants
Race/Ethnicity, Customized
Black
2 Participants3 Participants4 Participants9 Participants
Race/Ethnicity, Customized
Hispanic
7 Participants10 Participants6 Participants23 Participants
Race/Ethnicity, Customized
Other Not Specified
0 Participants1 Participants3 Participants4 Participants
Race/Ethnicity, Customized
White
77 Participants76 Participants80 Participants233 Participants
Sex: Female, Male
Female
57 Participants58 Participants62 Participants177 Participants
Sex: Female, Male
Male
71 Participants68 Participants68 Participants207 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
deaths
Total, all-cause mortality
0 / 1280 / 1260 / 128
other
Total, other adverse events
24 / 12826 / 12635 / 128
serious
Total, serious adverse events
0 / 1283 / 1264 / 128

Outcome results

Primary

Average Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score With Knee Extended at Weeks 4 and 6

The MAS-B was used to evaluate spasticity based on grading the resistance encountered in the principal muscle group (elbow and wrist) by means of passively moving a limb through its range of motion at a study specified velocity. The resistance encountered to passive stretch was graded using a 6-point scale where: 0=no increase in muscle tone (best) to 4=affected part(s) rigid in flexion or extension (worst). For analysis purposes, the MAS-B was recoded as follows: 0=1, 1=1, 1+=2, 2=3, 3=4, 4=5. The scores at Weeks 4 and 6 were averaged. A Mixed Model Repeated Measures (MMRM) model was used for analysis. A negative change from Baseline indicates improvement.

Time frame: Baseline (Day 1) to Weeks 4 and 6

Population: Participants from the mITT population, all randomized participants with a valid MAS-B baseline ankle score with knee extended and at least one post-baseline measurement at Weeks 2, 4, or 6 for the MAS-B of the ankle score with knee extended and the CGI by physician, with data available for analysis.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
BOTOX® 8 U/kgAverage Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score With Knee Extended at Weeks 4 and 6-1.06 score on a scaleStandard Error 0.071
BOTOX® 4 U/kgAverage Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score With Knee Extended at Weeks 4 and 6-1.01 score on a scaleStandard Error 0.072
PlaceboAverage Change From Baseline in Modified Ashworth Scale-Bohannon (MAS-B) Ankle Score With Knee Extended at Weeks 4 and 6-0.80 score on a scaleStandard Error 0.071
p-value: 0.0195% CI: [-0.453, -0.063]Mixed Model Repeated Measures
p-value: 0.03395% CI: [-0.405, -0.018]Mixed Model Repeated Measures
Primary

Average Clinical Global Impression (CGI) of Overall Change by Physician at Weeks 4 and 6

The CGI of overall change (improvement or worsening) was assessed by the physician considering the participant's clinical condition and severity of side effects using a 9-point scale where: -4=very marked worsening to +4=very marked improvement. The scores at Weeks 4 and 6 were averaged. A Mixed Model Repeated Measures (MMRM) model was used for analysis.

Time frame: Weeks 4 and 6

Population: Participants from the mITT population, all randomized participants with a valid MAS-B baseline ankle score with knee extended and at least one post-baseline measurement at Weeks 2, 4, or 6 for the MAS-B of the ankle score with knee extended and the CGI by physician, with data available for analysis.

ArmMeasureValue (LEAST_SQUARES_MEAN)Dispersion
BOTOX® 8 U/kgAverage Clinical Global Impression (CGI) of Overall Change by Physician at Weeks 4 and 61.65 score on a scaleStandard Error 0.09
BOTOX® 4 U/kgAverage Clinical Global Impression (CGI) of Overall Change by Physician at Weeks 4 and 61.49 score on a scaleStandard Error 0.091
PlaceboAverage Clinical Global Impression (CGI) of Overall Change by Physician at Weeks 4 and 61.36 score on a scaleStandard Error 0.089
p-value: 0.02395% CI: [0.04, 0.532]Mixed Model Repeated Measures
p-value: 0.29995% CI: [-0.115, 0.374]Mixed Model Repeated Measures
Secondary

Change From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)

The MTS measured the difference between slow and fast range of motion (R2-R1) and respective change from baseline to each posttreatment office visit. The MTS of the ankle was used to determine the passive range of movement at different movement velocities, V1 (as slow as possible) and V3 (as fast as possible) with the relative difference between a slow and fast velocity passive stretch determining the dynamic component of the muscle contracture for the joint. The investigator measured 2 joint angles by goniometer: the R1 angle which is the angle of catch after a fast velocity (V3) stretch and the R2 angle defined as the passive joint range of movement following a slow velocity (V1) stretch. The R2-R1 value indicated the level of the dynamic component of spasticity in the joint. The difference between R2 and R1 range of motion and respective change from baseline to each posttreatment office visit on the MTS was derived. An Analysis of Covariance (ANCOVA) model was used for analysis.

Time frame: Baseline (Day 1) to Weeks 2, 4, 6, 8 and 12

Population: Participants from the mITT population, all randomized participants with a valid MAS-B baseline ankle score with knee extended and at least one post-baseline measurement at Weeks 2, 4, or 6 for the MAS-B of the ankle score with knee extended and the CGI by physician, with data available for analysis at the given time-point.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
BOTOX® 8 U/kgChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 8-5.42 degreesStandard Error 1.317
BOTOX® 8 U/kgChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 6-6.65 degreesStandard Error 1.029
BOTOX® 8 U/kgChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 2-4.44 degreesStandard Error 1.023
BOTOX® 8 U/kgChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 4-6.11 degreesStandard Error 1.134
BOTOX® 8 U/kgChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 12-4.59 degreesStandard Error 1.07
BOTOX® 4 U/kgChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 6-7.23 degreesStandard Error 1.049
BOTOX® 4 U/kgChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 2-5.69 degreesStandard Error 1.024
BOTOX® 4 U/kgChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 4-6.80 degreesStandard Error 1.135
BOTOX® 4 U/kgChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 8-5.82 degreesStandard Error 1.308
BOTOX® 4 U/kgChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 12-3.07 degreesStandard Error 1.074
PlaceboChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 12-1.98 degreesStandard Error 1.057
PlaceboChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 8-3.36 degreesStandard Error 1.291
PlaceboChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 2-2.44 degreesStandard Error 1.0101
PlaceboChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 6-3.32 degreesStandard Error 1.029
PlaceboChange From Baseline in Severity of Spasticity of the Ankle With Knee Extended and Knee Flexed (R2-R1) Calculated Using the Modified Tardieu Scale (MTS)Change from Baseline to Week 4-4.69 degreesStandard Error 1.121
Comparison: Change from Baseline to Week 2p-value: 0.15895% CI: [-4.768, 0.779]ANCOVA
Comparison: Change from Baseline to Week 2p-value: 0.0295% CI: [-5.974, -0.524]ANCOVA
Comparison: Change from Baseline to Week 4p-value: 0.36395% CI: [-4.489, 1.648]ANCOVA
Comparison: Change from Baseline to Week 4p-value: 0.17195% CI: [-5.127, 0.914]ANCOVA
Comparison: Change from Baseline to Week 6p-value: 0.0295% CI: [-6.143, -0.525]ANCOVA
Comparison: Change from Baseline to Week 6p-value: 0.00695% CI: [-6.688, -1.148]ANCOVA
Comparison: Change from Baseline to Week 8p-value: 0.25495% CI: [-5.621, 1.491]ANCOVA
Comparison: Change from Baseline to Week 8p-value: 0.16595% CI: [-5.935, 1.014]ANCOVA
Comparison: Change from Baseline to Week 12p-value: 0.07895% CI: [-5.517, 0.296]ANCOVA
Comparison: Change from Baseline to Week 12p-value: 0.45195% CI: [-3.944, 1.758]ANCOVA
Secondary

Goal Attainment Score (GAS) as Assessed by Physician Using a 6-Point Scale

Two functional goals, one active and one passive, were selected by the participant and family in consultation with the physician investigator and/or treating physical therapist relative to the lower limb impairment due to spasticity. The physician assessed the achievement of the goals using a 6-point scale: where -3=worse than start to +2=much more than expected: improvements clearly exceed the defined therapeutic goal. An Analysis of Covariance (ANCOVA) model was used for analysis.

Time frame: Weeks 8 and 12

Population: Participants from the mITT population, all randomized participants with a valid MAS-B baseline ankle score with knee extended and at least one post-baseline measurement at Weeks 2, 4, or 6 for the MAS-B of the ankle score with knee extended and the CGI by physician, with data available for analysis at the given time-point.

ArmMeasureGroupValue (LEAST_SQUARES_MEAN)Dispersion
BOTOX® 8 U/kgGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 8, Active Goal0.10 score on a scaleStandard Error 0.108
BOTOX® 8 U/kgGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 8, Passive Goal0.19 score on a scaleStandard Error 0.115
BOTOX® 8 U/kgGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 12, Active Goal0.37 score on a scaleStandard Error 0.112
BOTOX® 8 U/kgGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 12, Passive Goal0.40 score on a scaleStandard Error 0.114
BOTOX® 4 U/kgGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 12, Passive Goal0.27 score on a scaleStandard Error 0.114
BOTOX® 4 U/kgGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 8, Active Goal-0.03 score on a scaleStandard Error 0.108
BOTOX® 4 U/kgGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 12, Active Goal0.09 score on a scaleStandard Error 0.113
BOTOX® 4 U/kgGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 8, Passive Goal0.18 score on a scaleStandard Error 0.114
PlaceboGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 12, Passive Goal0.00 score on a scaleStandard Error 0.112
PlaceboGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 8, Passive Goal-0.26 score on a scaleStandard Error 0.111
PlaceboGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 12, Active Goal-0.12 score on a scaleStandard Error 0.111
PlaceboGoal Attainment Score (GAS) as Assessed by Physician Using a 6-Point ScaleWeek 8, Active Goal-0.31 score on a scaleStandard Error 0.105
Comparison: Week 8, Active Goalp-value: 0.00595% CI: [0.126, 0.704]ANCOVA
Comparison: Week 8, Active Goalp-value: 0.04795% CI: [0.004, 0.573]ANCOVA
Comparison: Week 8, Passive Goalp-value: 0.00495% CI: [0.145, 0.756]ANCOVA
Comparison: Week 8, Passive Goalp-value: 0.00495% CI: [0.141, 0.74]ANCOVA
Comparison: Week 12, Active Goalp-value: 0.00195% CI: [0.191, 0.797]ANCOVA
Comparison: Week 12, Active Goalp-value: 0.15395% CI: [-0.081, 0.541]ANCOVA
Comparison: Week 12, Passive Goalp-value: 0.0195% CI: [0.1, 0.711]ANCOVA
Comparison: Week 12, Passive Goalp-value: 0.07895% CI: [-0.031, 0.571]ANCOVA

Source: ClinicalTrials.gov · Data processed: Feb 13, 2026